Eli Lilly and Company (LLY.DE) • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
You don't hold LLY.DE in your mock portfolio yet.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
A PE ratio of 41.04 and EPS of 26.46 indicate the market is assigning a premium multiple to Eli Lilly’s earnings, consistent with strong growth expectations and solid profitability. While the PE is elevated versus the broader market, it is in line with a high-growth, innovation-driven pharma profile, suggesting investors are confident in the company’s earnings trajectory. Overall, the valuation and earnings metrics point to a fundamentally strong and growth-oriented business, albeit with a rich price tag.
With the stock trading at €1,100 versus a 200-day moving average of €911.03, Eli Lilly is significantly above its longer-term trend, reflecting a strong prior uptrend and positive long-term momentum. However, an RSI of 34.89 places the stock near oversold territory, suggesting recent weakness or consolidation after a strong run. Taken together, the technical picture points to a strong long-term uptrend but a short-term cooling phase, making the setup more neutral in the near term.
Eli Lilly’s social media footprint is large and still growing modestly across most platforms, indicating sustained brand interest and engagement, particularly on Instagram. However, job openings at 679 are down 11.1% month over month, which may signal a moderation in hiring intensity or a move toward operational efficiency. Overall, alternative data points to a stable-to-positive brand and business presence, but with a slight cooling in growth-related hiring momentum.
Eli Lilly’s elevated PE and strong EPS support a bullish fundamental view, with the market clearly pricing in sustained growth and high-quality earnings. Technically, the stock remains in a long-term uptrend but is undergoing a short-term cooling phase, which tempers near-term enthusiasm but does not negate the broader positive trend. Alternative data is broadly stable to mildly positive, with strong brand presence and slightly softer hiring, reinforcing a generally constructive but not euphoric outlook.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started